Get the best in custom peptide synthesis from Mimotopes.

With fully customisable sequences, including adjustments to peptide length, a wide range of additional modifications, and options for the N and C termini, we can start building the ideal peptides for your research today.

As experts in custom peptide manufacturing, we can modify peptides to suit any purpose. They can be supplied individually or as part of a PepSet™Peptide Library. Modifications can be made at the terminal ends of the peptide or internally.

Cyclisation

An unrestrained peptide may be unstable and unreliable. Cyclisation constrains conformations to add stability and increase peptide function.

Here are some examples of the cyclised peptides we provide.

Biotinylation

Biotinylated peptides make ideal candidates for screening purposes. Biotinylation allows a peptide to be immobilised or detected, which is especially useful in a PepSet™ Peptide Library.

Conjugation

Conjugation is a versatile custom peptide modification with applications in antibody generation, affinity purification, and cell transport, to name a few.


It’s possible to produce an immunogen by conjugating a peptide to a carrier protein, couple peptides to gel for affinity purification, or build heterodimers to cross the cell membrane.

and many more

The list of peptide modifications goes on!

  • Stable isotope labeled peptides
  • FRET peptides
  • fluorescently labelled peptides
  • Branched peptides
  • Phosphorylation
  • Glycosylation
  • Methylation
  • Acetylation
  • Pegylation
  • Amidation
  • Succinylation
  • Carbamylation
  • Fatty acid capping
  • Photocleavable linkers

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

✉ useast@mimotopes.com
     uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Drug dealing goes digital Go to article: In this issueGo to article: ContentsGo to article: SyrenisGo to article: Astrix Go to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Thermo Fisher Scientific Company InsightGo to article: Thermo Fisher ScientificGo to article: CommentGo to article: Life sciences professionals prioritise quality over cost for PV automationGo to article: Slow progress for male contraceptive trialsGo to article: Accelerated approval designations in ChinaGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: In DepthGo to article: The dark consequences of supply shortagesGo to article: Digitising the pharma supply chainGo to article: Covid-19 vaccine pricing varies wildly by country and company Go to article: Psychedelics and mental health: the next big thing?Go to article: Schizophrenia drug landscape: a stagnant field on the cusp of change?Go to article: Are supercomputers set to transform pharma R&D?Go to article: BEA TechnologiesGo to article: LabcorpGo to article: In DataGo to article: North America's AI hiring boomGo to article: The pharma companies leading the way in artificial intelligenceGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue